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Repositionable and Retrievable Lotus
Transcatheter Aortic Replacement Valve
in 120 High-Risk Surgical Patients With
Severe Aortic Stenosis
Results of the REPRISE II StudyIan T. Meredith, AM, MBBS, PHD,a Darren L. Walters, MD,b Nicolas Dumonteil, MD,c Stephen G. Worthley, MD,d
Didier Tchétché, MD,e Ganesh Manoharan, MD,f Daniel J. Blackman, MD,g Gilles Rioufol, MD,h
David Hildick-Smith, MD,i Robert J. Whitbourn, MD,j Thierry Lefèvre, MD,k Rüdiger Lange, MD,l Ralf Müller, MD,m
Simon Redwood, MD,n Ted E. Feldman, MD,o Dominic J. Allocco, MD,p Keith D. Dawkins, MDpABSTRACTOBJECTIVES This analysis presents the ﬁrst report of 1-year outcomes of the 120 patients enrolled in the REPRISE II
(Repositionable Percutaneous Placement of Stenotic Aortic Valve Through Implantation of Lotus Valve System–
Evaluation of Safety and Performance) study.
BACKGROUND The fully repositionable and retrievable Lotus Valve (Boston Scientiﬁc, Marlborough,
Massachusetts) was designed to facilitate accurate positioning, early valve function, and hemodynamic stability
during deployment and to minimize paravalvular regurgitation in patients undergoing transcatheter aortic valve
replacement.
METHODS The study enrolled 120 symptomatic patients 70 years of age or older at 14 centers in Australia and Europe.
Patients had severe calciﬁc aortic stenosis and were deemed to be at high or extreme risk of surgery based on assessment
by the heart team.
RESULTS The mean age was 84.4  5.3 years, 57% (68 of 120) of patients were women, and the mean Society of
Thoracic Surgeons score was 7.1  4.6. The mean baseline aortic valve area was 0.7  0.2 cm2, and the mean
transvalvular pressure gradient was 46.4  15.0 mm Hg. All patients were successfully implanted with a Lotus Valve,
and 1-year clinical follow-up was available for 99.2% (119 of 120 of patients). The mean 1-year transvalvular aortic
pressure gradient was 12.6  5.7 mm Hg, and the mean valve area was 1.7  0.5 cm2. A total of 88.6% patients had
no or trivial paravalvular aortic regurgitation at 1 year by independent core lab adjudication, and 97.1% of patients
were New York Heart Association functional class I or II. At 1 year, the all-cause mortality rate was 10.9% (13 of 119
patients), disabling stroke rate was 3.4% (4 of 119 patients), disabling bleeding rate was 5.9% (7 of 119 patients), with
no repeat procedures for valve-related dysfunction. A total of 31.9% (38 of 119 patients) underwent new permanent
pacemaker implantation at 1 year.
CONCLUSIONS At 1 year of follow-up, the Lotus Valve demonstrated excellent valve hemodynamics, no
moderate or severe paravalvular regurgitation, and signiﬁcant and sustained improvement in New York Heart
Association functional class status, with good clinical outcomes. (Repositionable Percutaneous Placement of
Stenotic Aortic Valve Through Implantation of Lotus Valve System–Evaluation of Safety and Performance
[REPRISE II]; NCT01627691) (J Am Coll Cardiol Intv 2016;9:376–84) © 2016 by the American College of
Cardiology Foundation.
AB BR E V I A T I O N S
AND ACRONYM S
NYHA = New York Heart
Association
SF-12 = 12-Item Short-Form
Health Survey
TAVR = transcatheter aortic
valve replacement
TTE = transthoracic
echocardiography
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377T he repositionable and fully retrievable LotusValve (Boston Scientiﬁc, Marlborough, Mas-sachusetts) was designed to facilitate accu-
rate primary positioning, early valve function, and
hemodynamic stability during deployment and to
minimize paravalvular regurgitation in patients with
severe aortic stenosis who are deemed at high or
extreme surgical risk (1). The Lotus Valve has
received CE mark in Europe based in part on the
initial results of the REPRISE II (Repositionable Percu-
taneous Placement of Stenotic Aortic Valve Through Im-
plantation of Lotus Valve System–Evaluation of SafetySEE PAGE 385and Performance) study (2). At 30 days, the mean aortic
valve pressure gradient was 11.5  5.2 mm Hg, with a
1-sided 98.7% upper conﬁdence limit of 12.6, which was
signiﬁcantly less than the predetermined performance
goal of 18 mm Hg (1-sample t test, p < 0.0001), and,
thus, the primary device performance endpoint was
met. The primary safety endpoint, deﬁned as all-cause
mortality at 30 days, was 4.2% (5 of 119 patients). The
observed rate ofmoderate or severe paravalvular regurgi-
tation was low at 30 days, with only 1 patient (1.0%) hav-
ing moderate paravalvular regurgitation and no patients
having severeparavalvular regurgitation (2). This analysis
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METHODS
The REPRISE II study design and methods
were previously described in detail and are
brieﬂy summarized here (2).
DEVICE DESCRIPTION. The Boston Scientiﬁc
Lotus Valve System consists of a woven
nitinol-framed bioprosthesis with bovine pericardium
leaﬂets, which is pre-mounted on a transfemoral
catheter delivery system. The valve is expanded via a
controlled mechanical expansion that facilitates
repositioning or full retrieval even after the valve is
fully expanded and locked in its ﬁnal position; rapid
pacing is not required during implantation, and the
valve functions early in deployment, providing he-
modynamic stability. The design also incorporates a
polymeric outer Adaptive Seal designed to minimize
paravalvular regurgitation. The Lotus Introducer Set is
composed of a dilator and an introducer sheath and is
used as an accessory in the procedure. Two valve sizes
were available in the REPRISE II study: 23 mm (for
patients with a native aortic annulus of 19 to 23 mm)
and 27 mm (for patients with a native aortic annulus of
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378STUDY DESIGN. The REPRISE II study is a prospective,
single-arm, multicenter trial evaluating the safety and
effectiveness of the Lotus Valve at 14 centers in
Australia, France, Germany, and the United Kingdom.
The primary device performance endpoint was the
mean aortic valve pressure gradient at 30 days post-
procedure. The primary device performance endpoint
was compared with a performance goal of 18 mm Hg.
The primary safety endpoint was the rate of all-cause
mortality at 30 days post-procedure. One-year clin-
ical outcomes were pre-speciﬁed as secondary end-
points in the study protocol.
The REPRISE II study complied with the principles
of the Declaration of Helsinki and all local and
country-speciﬁc regulations. A locally appointed
ethics committee approved the research protocol at
each site, and all patients (or their guardians) pro-
vided written informed consent before enrollment.
PATIENT SELECTION, PROCEDURE, AND FOLLOW-UP.
Patients 70 years of age or older with symptomatic
severe aortic stenosis (deﬁned as an aortic valve area
of <1.0 cm2 or aortic valve area index of <0.6 cm2/m2)
and a mean pressure gradient >40 mm Hg or a jet ve-
locity >4 m/s were eligible for enrollment. Other key
inclusion criteria were New York Heart Association
(NYHA) functional class II or greater heart failure,
native aortic annulus size between 19 and 27mm, and a
Society of Thoracic Surgeons (STS) score $8% or
considered high risk for surgical aortic valve replace-
ment based on assessment by the multidisciplinary
Heart Team. An independent Case Review Committee
also conﬁrmed patient eligibility for the study before
enrollment. The constitution and function of the Case
Review Committee has been previously described (2).
Key exclusion criteria included acute myocardial
infarction within 30 days, stroke or transient ischemic
attack within 6 months, compromised kidney function
(deﬁned as dialysis dependent or creatinine level >3.0
mg/dl), unicuspid or bicuspid aortic valve, preexisting
aortic or mitral prosthetic heart valve or ring, $3þ
mitral or $3þ aortic regurgitation, left ventricular
ejection fraction <30%, or femoral artery anatomy
unsuitable for the use of the Lotus Valve Introducer.
All investigators completed comprehensive train-
ing before performing implantations in patients and
received on-site proctorship during their initial im-
plantation procedures. Patients were assessed by
transthoracic echocardiography, coronary angiog-
raphy, computed tomography angiography of the aortic
valve and the entire aorta, and computed tomography
or invasive angiography of the iliofemoral system. The
choice of valve size was determined in all cases by
systematic analysis of the diameter, perimeter, and
area of basal plane annulus, left ventricular outﬂowtract, and transsinus dimensions using the 3Mensio
MDCT Aortic Valve Analysis software (3MensioMedical
Imaging BV, Bilthoven, the Netherlands). Metrics to aid
the choice of either the 23-mm diameter or 27-mm
diameter prosthesis were previously described (2).
Per protocol, all implantations were performed via
the transfemoral route. Balloon valvuloplasty was
required before insertion of the Lotus Valve System.
Patients were considered enrolled in the study as
soon as an attempt was made to insert the Lotus
Valve System into the femoral artery sheath. All
enrolled patients were considered for analysis in the
study, and no roll-in patients were allowed. Antico-
agulant therapy (e.g., unfractionated heparin) was
administered per local standard of care during the
implantation procedure, with a recommended target
activated clotting time of $250 s during the index
procedure. Patients were required to be treated with
aspirin and a thienopyridine before implantation of
the Lotus Valve and for at least 1 month after valve
implantation, and daily aspirin was recommended
indeﬁnitely thereafter per local standard of care (2,3).
Clinical follow-up occurred at discharge or 7 days
(whichever came ﬁrst), 30 days, 3 months, 6 months,
and 1 year, and will continue annually to 5 years.
Neurological status was assessed in all patients pre-
and post-procedure by a qualiﬁed neurologist. Health
status was evaluated using the 12-Item Short-Form
Health Survey (SF-12) and EQ-5D Quality of Life
questionnaires administered at baseline, 1 month,
6 months, and 1 year.
DEFINITIONS. Safety and effectiveness were assessed
according to Valve Academic Research Consortium
2 metrics (4). An independent clinical events committee
adjudicated all VARC-related endpoints. The REPRISE II
study used 4 independent core laboratories for the
assessment of the following: 1) angiography and
computed tomography/radiographic data (Harvard
Medical Faculty Physicians at Beth Israel Deaconess
Medical Center, Boston, Massachusetts; 2) echocardiog-
raphy (MedStar Health Research Institute, Washington,
DC); 3) electrocardiography (Harvard Clinical Research
Institute, Boston, Massachusetts); and 4) pathology
(CV Path Institute, Inc., Gaithersburg, Maryland).
STATISTICAL METHODS. Patient demographics, risk
factors, device performance, and clinical outcomes
were summarized using descriptive statistics for
continuous variables and frequency tables for
discrete variables. All endpoints were analyzed on an
intent-to-treat basis. Change from baseline to 1 year
was assessed using paired Student t tests for health
status data; change from baseline for hemodynamic
measures was assessed using estimates of the
FIGURE 1 Study Flow
Patient disposition to 1 year. F/U ¼ follow-up; TTE ¼ transthoracic echocardiography.
TABLE 1 Baseline Patient and Echocardiographic Characteristics (N ¼ 120)
Age, yrs 84.4  5.3 (120/120)
Female 56.7 (68/120)
Society of Thoracic Surgeons score (version 2.73), % 7.1  4.6 (120/120)
Society of Thoracic Surgeons Plus score, % 11.8  8.0 (120/120)
EuroSCORE 2011, % 6.9  5.8 (120/120)
New York Heart Association functional class III or IV 75.8 (91/120)
Medically treated diabetes 22.5 (27/120)
History of atrial ﬁbrillation 40.8 (49/120)
Baseline right bundle branch block 7.5 (9/120)
Baseline left bundle branch block 6.7 (8/120)
Baseline ﬁrst-degree atrioventricular block 17.5 (21/120)
Permanent pacemaker at baseline 6.7 (8/120)
Frailty Indices
5-m gait speed, s (frail if >6 s) 9.2  6.7 (119)
Mean maximum grip strength, kg (frail if #18 kg) 20.1  12.8 (120)
Katz index (frail if <6) 5.7  0.9 (120)
Mini-Cognitive Assessment for Dementia (frail if <4) 3.6  1.4 (120)
Echocardiography measurements*
Aortic valve area, cm2 0.7  0.2 (97/120)
Mean aortic gradient, mm Hg 46.4  15.0 (104/120)
Peak aortic gradient, mm Hg 76.5  23.6 (104/120)
Left ventricular ejection fraction, % 54.3  10.7 (61/120)
Mitral regurgitation (moderate/severe), % 11.6 (13/112)
Aortic regurgitation (moderate/severe), % 15.2 (17/112)
Values are mean  SD (n/N) or % (n/N). *Core laboratory assessment.
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379repeated measures and a hierarchical analysis of
variance model with unstructured covariance and
with random effects of country and center where
center was nested within the country. Change from
baseline for NYHA functional class was assessed using
the paired Wilcoxon signed rank test. All calculations
were performed using SAS version 9.2 or later (SAS
Institute, Cary, North Carolina).
RESULTS
All 120 patients enrolled in the REPRISE II study
received a Lotus Valve; of these, 61 (50.8%) received a
23-mm valve and 59 (49.2%) received a 27-mm valve.
Successful vascular access, delivery, and deployment
of the Lotus Valve along with successful retrieval of
the delivery system occurred in all 120 patients.
Repositioning or retrieval of the valve occurred in 32
patients (26.7%). One patient withdrew consent on
day 13; thus, 1-year follow-up or death data were
available for 99.2% (119 of 120 patients) (Figure 1).
Thirteen patients died within 1 year, and trans-
thoracic echocardiography assessment was com-
pleted in 99 of 106 eligible patients (93.4%). Baseline
patient and echocardiographic characteristics,
including frailty characteristics, are provided in
Table 1. The majority of patients were female (57%),
with a mean age of 84 years and an STS score (version
2.73) of 7.1  4.6%.
VALVE PERFORMANCE AT 1 YEAR. At baseline, the
effective aortic valve oriﬁce area was 0.7  0.2 cm2,
and the mean aortic transvalvular gradient was
46.4  15.0 mm Hg (Figure 2). At hospital discharge,
the mean effective oriﬁce area had improved to 1.6 
0.4 cm2 (p < 0.001 vs. baseline), and the mean aortic
transvalvular gradient also improved to 12.1 
4.4 mm Hg (p < 0.001 vs. baseline). These results
were sustained at 1 year, with an effective oriﬁce area
of 1.7  0.5 cm2 (p < 0.001 vs. baseline) and a mean
aortic gradient of 12.6  5.7 mm Hg (p < 0.001 vs.
baseline). There was no or trivial paravalvular regur-
gitation at 1 year in 88.6% of patients, and no patient
had moderate or severe paravalvular aortic regurgi-
tation at 1-year follow-up, as assessed by the echo-
cardiographic core laboratory (Figure 3).
NYHA FUNCTIONAL CLASS AND HEALTH STATUS AT
1 YEAR. At baseline, the majority of patients (75.8%)
were NYHA functional class III or IV (Figure 4). Post-
procedure, there was steady improvement in NYHA
functional class overall such that 97.2% of patients
were either functional class I or II at 1 year (p <
0.001 vs. baseline and p ¼ 0.04 vs. 30 days). Health-
related quality of life was signiﬁcantly increasedfrom baseline according to the SF-12 questionnaire,
with the physical health summary score improving
from 35.0  9.2 at baseline to 38.2  10.8 at 1 year
(p ¼ 0.004). The mental health summary score was
unchanged at 1 year (49.7  10.4 and 51.3  10.6 at
baseline and 1 year, respectively; p ¼ 0.55) (Table 2).
In addition, self-rated health according to the EQ-5D
FIGURE 2 Hemodynamic Parameters to 1 Year
Effective oriﬁce area (EOA) and mean aortic gradient. D/C ¼ discharge; 30D ¼ 30 days;
1Y ¼ 1 year.
FIGURE 3 Aortic R
Baseline and paraval
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380visual analog scale signiﬁcantly improved from 61.6
 17.9 at baseline to 70.1  18.0 at 1 year (p <
0.001). There was no change from baseline in health
status according to the EQ-5D index values
(Table 2).egurgitation
vular aortic regurgitation to 1 year. 7d ¼ 7 days.SAFETY OUTCOMES AT 1 YEAR. All-cause mortality
at 1 year was 10.9% (Table 3), representing 3 new
cardiovascular and 5 new noncardiovascular deaths
after the previously published primary endpoint of
30 days. Disabling stroke was 3.4%, and nondisabling
stroke was 5.9%, representing 2 additional disabling
and 2 nondisabling strokes that occurred between
30 days and 1 year, for a total stroke rate of 9.2% at
1 year. There was no signiﬁcant difference in 1-year
stroke rate between patients with and without repo-
sitioning or retrieval of the valve during implantation
(9.4% [3 of 32 patients] with repositioning/retrieval vs
9.1% [8 of 88 patients] without repositioning/
retrieval; p ¼ 1.00). One additional case of life-
threatening bleeding (the patient required trans-
fusion following hip replacement surgery) was
reported at day 301, and 1 case of prosthetic valve
endocarditis (associated with urosepsis) was reported
at day 165, but otherwise the Valve Academic
Research Consortium 2 safety endpoints remained
largely unchanged at 1 year from those observed at 30
days (Table 3).
Four additional patients required implantation of a
new permanent pacemaker between 30 days and
1 year for an overall 1-year rate of 31.9%. Among pa-
tients with a new pacemaker at 1 year, 57.9%
had $10% overstretch of the left ventricular outﬂow
tract by area, and nearly 40% (39.5%) had $10%
overstretch of the annulus by area (Table 3). Signiﬁ-
cantly more patients with a pacemaker at 1 year had
>10% left ventricular outﬂow tract overstretch
compared with patients without a pacemaker (57.9%
vs. 33.8%, respectively; p ¼ 0.01). There was a trend
toward a greater proportion of patients with >10%
annular overstretch among patients with a pacemaker
at 1 year, but the difference did not reach statistical
signiﬁcance (39.5% vs. 24.3%; p ¼ 0.10).
At 1 year, there were no repeat procedures for
valve-related dysfunction and no valve thrombosis,
migration, or embolization (Table 3).
DISCUSSION
In this 1-year follow up of the REPRISE II study, we
report that the Lotus Valve has favorable valve per-
formance and sustained hemodynamic and clinical
beneﬁts. These observations are entirely consistent
with those reported in the 30-day primary endpoint
paper (1). The signiﬁcant increase from baseline to
30 days in mean aortic valve gradient and effective
aortic valve oriﬁce area were sustained at 1 year and
were consistent with those reported for other trans-
catheter valves in serial echocardiographic studies
after transfemoral valve implantation (5–10). At
FIGURE 4 Change in NYHA Status
New York Heart Association (NYHA) functional class status to 1 year.
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3811 year, there were no repeat procedures for valve-
related dysfunction, and no valve thrombosis,
migration, or embolization. Also notable was the lack
of valve-in-valve procedures or the need for late
surgical conversion with the Lotus Valve.
Transcatheter aortic valve replacement (TAVR)
provides a clinically viable alternative to conventional
surgical aortic valve replacement for patients at high or
extreme risk of perioperative mortality. Recent data
from the U.S. randomized CoreValve study indicate a
survival advantage for TAVR at 1 year that is preserved
through 2 years and that freedom from death or stroke
remains lower with TAVR than surgical aortic valve
replacement (11). Although these data are excellent,
several limitations remain in ﬁrst-generation TAVR
devices, including challenges in valve positioning and
paravalvular aortic regurgitation. The Lotus Valve was
designed to aid accurate primary positioning without
the need for rapid pacing or hemodynamic stress,
provide the opportunity to reposition or retrieve the
valve if necessary, and decrease the risk of para-
valvular leak, all of which are factors that may improve
both short- and long-term clinical outcomes.
In this study, patients implanted with the Lotus
Valve experienced a clinically and statistically sig-
niﬁcant improvement in health and quality of life
status at 30 days, which was also maintained through
1 year. At 1 year, 97.2% of patients were NYHA func-
tional class I or II, a notable and highly signiﬁcant
(p < 0.001) increase from baseline, where 76% of pa-
tients were functional class III or IV, and a further
signiﬁcant improvement from 30 days, where 91% of
patients were functional class I or II (p ¼ 0.04 for
30 days to 1 year). Similarly, the 3.2-point increase
from baseline in the SF-12 physical summary score
observed at 1 year, although signiﬁcant (p ¼ 0.004),
also exceeded the minimally important difference of
2.5 points that is generally considered to be clinically
meaningful with this instrument (12). Although the
EQ-5D has been used in studies of cardiovascular
disease, considerable heterogeneity between studies
has limited efforts to establish minimally important
differences with this metric (13,14); however, in
studies of patients with cancer, minimally important
differences in the EQ-5D ranged from 0.06 to 0.07 and
in visual analog scale scores from 8 to 12 (15). In this
regard, the signiﬁcant (p < 0.001) change from base-
line to 1 year of 8.5 in visual analog scale scores in the
current study corroborate the changes observed in
NYHA functional class assessment and the SF-12, and
the EQ-5D and SF-12 results at 6 months and 1 year
observed in this study are concordant with other se-
rial studies of quality of life in patients with aortic
stenosis (16–18).Independent core laboratory adjudication of the
extent of paravalvular regurgitation indicated 86.4%
of patients had no paravalvular regurgitation at
1 year, and an additional 2.3% had only a trace of
regurgitation. No patient was adjudicated to have
moderate or severe paravalvular regurgitation at
1 year. Moderate/severe paravalvular regurgitation
has been found in 9% to 25% of patients in reports
using ﬁrst-generation TAVR devices and is associated
with increased mortality (7,19–22). Although clear
causality has not been established, the mechanisms
underlying the association are being elucidated and
may, in part, involve a blunted remodeling response
of the left ventricle after TAVR (23) or myocardial
ischemia due to a higher pressure gradient associated
with paravalvular regurgitation into a hypertrophied
ventricle (24,25).
All-cause mortality and disabling stroke rates at
1 year were 10.9% and 3.4%, respectively. These
rates are at least comparable to those reported with
other contemporary transfemoral transcatheter aortic
valves. Although cross-trial comparisons should be
TABLE 3 Selected V
Eve
All-cause mortality
Cardiovascular morta
All stroke
Disabling stroke
Nondisabling stroke
Life-threatening/disabl
Major bleeding
Acute kidney injury (st
Periprocedural (#72 h)
Major vascular complic
Repeat procedure (surg
for valve-related
Cardiac tamponade
Myocardial infarction (
Myocardial infarction (
Hospitalization for valv
congestive heart
New-onset atrial ﬁbrill
Prosthetic valve endoc
Valve thrombosis, migr
New permanent pacem
Left ventricular outﬂ
overstretch $10%
Annulus area overstr
Values are % (n/N). *Per
transfusion after hip replac
at day 165.
TABLE 2 Health Status at 6 Months and 1 Year
Measure Baseline 6 Months p Value* 1 Year p Value*
12-Item Short-Form Health Survey
Physical Summary Score 35.0  9.2 (120)
(12.6, 58.7)
38.9  10.4 (107)
(13.3, 62.1)
<0.001 38.2  10.8 (105)
(7.0, 59.1)
0.004
Mental Health Summary Score 49.7  10.4 (120)
(19.0, 69.8)
50.9  11.0 (107)
(19.0, 76.1)
0.57 51.3  10.6 (105)
(20.2, 77.8)
0.55
EQ-5D
EQ-5D index values 0.7  0.2 (120)
(0.2, 1.0)
0.7  0.3 (107)
(0.4, 1.0)
0.41 0.7  0.2 (105)
(0.05, 1.00)
0.50
EQ visual analog scale 61.6  17.9 (120)
(10.0, 99.0)
70.8  19.0 (107)
(5.0, 100.0)
<0.001 70.1  18.0 (105)
(25.0, 100.0)
<0.001
Values are mean  SD (n) (min, max). *Versus baseline.
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382approachedwith caution given a lack of randomization
or propensity matching, we note that in randomized
trials of other valves implanted transfemorally, 1-year
mortality rates ranged from 14.2% to 24.3% for the
Medtronic CoreValve (baseline STS scores: 5.3 to 10.3)
(5,7,9) and from 22.5% to 30.7% for the Edwards
SAPIEN/SAPIEN XT (baseline STS scores: 10.3 to 11.2)
(6,8). Similarly, major/disabling stroke rates at 1 year
were reported in those trials ranged from 2.2% to 5.8%
for the CoreValve (5,7,9) and from 4.5% to 7.8% for
SAPIEN/SAPIEN XT (6,8).ARC 2 Safety Endpoints at 1 Year
nt* New Events 30 Days to 1 Year At 1 Year
6.7 (8/119) 10.9 (13/119)
lity 2.5 (3/119) 6.7 (8/119)
3.4 (4/119) 9.2 (11/119)
1.7 (2/119) 3.4 (4/119)
1.7 (2/119) 5.9 (7/119)
ing bleeding 0.8 (1/119)† 5.9 (7/119)
3.4 (4/119) 21.0 (25/119)
age 2 or 3) 0 (0/119) 3.4 (4/119)
coronary obstruction 0 (0/119) 0.8 (1/119)
ations 0 (0/119) 2.5 (3/119)
ery or interventional)
dysfunction
0 (0/119) 0 (0/119)
0 (0/119) 4.2 (5/119)
#72 h) 0 (0/119) 3.4 (4/119)
>72 h) 0 (0/119) 0 (0/119)
e-related symptoms or
failure
0.8 (1/119) 5.0 (6/119)
ation 0.8 (1/119) 5.9 (7/119)
arditis 0.8 (1/119)‡ 0.8 (1/119)
ation, or embolization 0 (0/119) 0 (0/119)
aker 3.4 (4/119) 31.9 (38/119)
ow tract area 75.0 (3/4) 57.9 (22/38)
etch $10% 25.0 (1/4) 39.5 (15/38)
independent adjudication by the clinical events committee. †The patient required
ement surgery on day 301. ‡Prosthetic valve endocarditis associated with urosepsisThe rate of permanent pacemaker implantation at
1 year was 31.9% (38 of 119 patients) in the REPRISE II
study. Reported rates for the need for pacemaker
implantation at 1 year post-TAVR have ranged from
1.8% to 11.5% with SAPIEN/SAPIEN XT (6,8,21,26,27)
and 19.1% to 30.3% with CoreValve (5,7,9,20–22).
Pacemaker implantation has not been associated
with an increased risk of mortality in the majority of
published studies (28–30), although the long-term
consequence of the need for pacemaker implanta-
tion should be considered for selected patient pop-
ulations, such as patients with poor left ventricular
function, younger patients, or those with lower sur-
gical risk. Although 1 recent study suggested poorer
outcomes when a pacemaker is implanted after
deployment of the SAPIEN valve (31), another study
suggested improved survival associated with pace-
maker implantation (32). Greater than 10% over-
stretch, particularly of the left ventricular outﬂow
tract, was associated with a signiﬁcantly increased
rate of permanent pacemakers in the REPRISE II
study; the availability of additional valve sizes may
help in this regard.
STUDY LIMITATIONS. First, this was not a random-
ized, double-blind, active-control trial. The U.S. Food
and Drug Administration approval REPRISE III study
that is currently enrolling patients will provide a
head-to-head randomized comparison with the Core-
Valve in w1,000 patients and is expected to add
considerably to the body of evidence for TAVR. Sec-
ond, although pre-speciﬁed in the study protocol, our
study was not statistically powered for clinical end-
points at 1 year, so those results should be considered
hypothesis generating only.
CONCLUSIONS
At 1 year in the main 120-patient cohort, the REPRISE
II study demonstrated sustained and excellent valve
PERSPECTIVES
WHAT IS KNOWN? TAVR is a viable alternative to conventional
surgical aortic valve replacement in patients considered to be at
high or extreme risk of a major perioperative complication or
death. Although emerging data from larger randomized,
controlled trials and registries conﬁrm the safety and effective-
ness of TAVR in general, current technologies have technical
limitations that limit the wider translation of trial results and may
affect individual patient outcomes.
WHAT IS NEW? This study examines a new TAVR technology
with several design features intended to address current device
limitations, including the capability of full repositioning and
retrieval of the prosthesis should this be required and an adaptive
seal on the outer perimeter of the expanded prosthesis to mini-
mize paravalvular regurgitation, which is known to be associated
with poorer long-term patient outcomes.
WHAT IS NEXT? Initial results with the Lotus Valve from this
REPRISE II CE-mark study demonstrate very promising results for
the improved treatment of aortic stenosis; however, longer term
follow-up and head-to-head comparisons with other available
technologies will be needed to determine the wider clinical utility
of the technological advancements of the Lotus Valve.
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383hemodynamic results, with very low rates of
paravalvular regurgitation. More than 88% of patients
had no or trivial paravalvular regurgitation, and
no patient had moderate or severe paravalvular
regurgitation. Additionally, we observed signiﬁcant
and sustained improvement in NYHA functional
class, signiﬁcantly improved quality of life measures
from baseline, and adverse event rates consistent
with those reported for other transcatheter valves.
The 1-year results of this study continue to suggest
that the fully repositionable and retrievable Lotus
Valve is a valuable new addition to the available de-
vices for the minimally invasive treatment of aortic
stenosis.
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